YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,…
Key Points Interested in Sera Prognostics, Inc.? Here are five stocks we like better. Revenue remained modest at $30,000 in Q2, up from $17,000 a year earlier, while the net loss widened to $9.1 million. Sera ended the quarter with $80.3 m…
Viatris (VTRS) came out with quarterly earnings of $0.69 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This…
Agilon Health (AGL) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $6.25 per share a year ago. These figures are adjusted for non-recurring items. Th…
SALT LAKE CITY, June 24, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information, today announced its part…
Image source: The Motley Fool. DATE Wednesday, May 6, 2026 at 5 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Zhenya Lindgardt Chief Financial Officer — Austin Eretz Full Conference Call Transcript Genya Lyngard, Presid…
Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio, the higher the stock value. The reasoning behind this is s…
Sera Prognostics, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Transition from Clinical Validation to Market Adoption The company successfully transitioned from a research-heavy phase to commercialization following the January 2026…
Earnings Call Insights: Sera Prognostics (SERA) Q4 2025 MANAGEMENT VIEW * President and CEO Evguenia Lindgardt highlighted 2025 as a pivotal year, emphasizing, "2025 was a critical year for Sera, finalizing our PRIME publication to advance…
Sera Prognostics logo Key Points PRIME was published in January 2026 and management highlighted it showed a 56% and 32% reduction in births before 32 and 35 weeks respectively, plus an asserted ~20% reduction in NICU admissions, positionin…
[Young female scientist working in laboratory] Solskin Pharmaceutical (PJP [https://seekingalpha.com/symbol/PJP]), (XPH [https://seekingalpha.com/symbol/XPH]), (PPH [https://seekingalpha.com/symbol/PPH]) and biotechnology stocks (XBI [http…
Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director BILLERICA, Mass., November 20, 2025--(BUSINESS WIRE)--Quanterix Corporation ("Qu…
Earnings Call Insights: Sera Prognostics (SERA) Q3 2025 MANAGEMENT VIEW * Evguenia Lindgardt, President and CEO, stated that "Building on the momentum from our PRIME study and ongoing commercialization efforts in the third quarter of 2025…
* Sera Prognostics press release [https://seekingalpha.com/pr/20307287-sera-prognostics-reports-third-quarter-2025-financial-results] (SERA [https://seekingalpha.com/symbol/SERA]): Q3 GAAP EPS of -$0.16 beats by $0.04. * Revenue of $0.01M…
Premier, Inc. (PINC) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.34 per share a year ago. These figures are adjusted for non-recurring items.…
CVS Health (CVS) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items. This…
SALT LAKE CITY, Oct. 1, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker testing to help deliver information to…
Earnings Call Insights: Sera Prognostics (SERA) Q2 2025 MANAGEMENT VIEW * President and CEO Evguenia Lindgardt stated that "we're continuing to advance Sera's commercial progress and building momentum in our business." She highlighted ongo…
SERA PROGNOSTICS INC-A (NASDAQ:SERA [https://www.chartmill.com/stock/quote/SERA/profile]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES, EPS BEATS ESTIMATES Sera Prognostics Inc., a company specializing in maternal and neonatal health diagnosti…
Austin Aerts, the Chief Financial Officer of $SERA, sold 945 shares of the company on 06-10-2025 for an estimated $1,398. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.3% of their shares of this…
SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,…
Buying stocks that can make you millions is any investor’s dream. That is why some investors consider micro-cap or small-cap stocks trading under $10. Doing so lets them buy into the business and potentially make a killing if their thesis…
Sera Prognostics, Inc. (SERA) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2022. This widely-known consensus outlook gives a good sense of the company's…
Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy SALT LAKE CITY, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Preg…
SALT LAKE CITY, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patie…
SALT LAKE CITY, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patie…
SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patie…
SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patien…